|
|
|
Home >
Health Conditions > Osteoporosis >
Evista (raloxifene)
Evista® (raloxifene)
Where to Purchase:
Related Topics:
News & Research:
-
Drugs Can Cut Breast Cancer Risk for Some, Task Force Finds - WebMD,
4/15/13 - "One of the report's key findings was that
studies of tamoxifen reported a decrease in breast cancer incidence from
23.5 per 1,000 women in the placebo group to 16.5 per 1,000 among women
taking tamoxifen over a five-year period ... Tamoxifen is more effective at
reducing breast cancer risk, but it has more side effects ... there were
five fewer cancers per 1,000 women taking tamoxifen when compared with
raloxifene ... For tamoxifen, 8.6 per 1,000 women experienced a blood clot
compared with 4.6 per 1,000 in the "control" group ... The rates of
endometrial cancer, or cancer of the uterus, and cataracts were also higher
for women taking tamoxifen, but not for those taking raloxifene"
-
Medications Effective In Reducing Risks For Breast Cancer Can Also Cause
Serious Side Effects - Science Daily, 9/18/09 -
"The most common side effects for tamoxifen are flushing and other vasomotor
symptoms (e.g., night sweats, hot flashes), vaginal discharge and other
vaginal symptoms such as itching or dryness; for raloxifene, side effects
include vasomotor symptoms and leg cramps; and for tibolone, side effects
include vaginal bleeding ... Tamoxifen increases risks of endometrial
cancer, hysterectomies and cataracts compared with the other drugs.
Tamoxifen and raloxifene increase risk of blood clots, although tamoxifen's
risk is greater. Tibolone carries an increased risk of stroke"
-
Agent Reduces Breast Cancer Risk in Two Groups of Women - Physician's
Weekly Article, 12/17/07 - "raloxifene hydrochloride
reduced the risk of invasive breast cancer by 44% to 71% by blocking
estrogen receptors in the breast"
-
FDA Panel OKs Evista for Breast Cancer - WebMD, 7/24/07
-
Raloxifene Reduces Breast Cancer Risk in Postmenopausal Women at All Risk
Levels - Doctor's Guide, 9/13/06 -
"use of raloxifene was associated with a 58 percent
reduction in breast cancer risk in women without a family history of the
disease, and an 89 percent reduction in risk for women with a family history
of breast cancer" - See raloxifene at
OffshoreRx1.com.
-
Evista: Help for Breast Cancer, Heart? - WebMD, 7/12/06
-
Major Study Evaluates Benefits and Risks of Tamoxifen and Raloxifene for
Reducing the Risk of Breast Cancer - Doctor's Guide, 7/4/06
-
Benefits and Risks of Tamoxifen, Raloxifene for Reducing Risk of Breast
Cancer - Doctor's Guide, 6/6/06
-
Osteoporosis Drug Raloxifene Shown to Be as Effective as Tamoxifen in
Preventing Invasive Breast Cancer - Doctor's Guide, 4/17/06
-
Lilly Announces Preliminary Coronary and Breast Cancer Results from
Raloxifene Use for The Heart (RUTH) Study - Doctor's Guide, 4/12/06
-
Drug May Slow Prostate Cancer - WebMD, 3/29/06
-
Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit
Prostate Cancer Patients - Science Daily, 3/24/06
-
Low Endogenous Estradiol, Raloxifene (Evista), Linked to Decreased Stroke
Risk in Postmenopausal Women - Doctor's Guide, 2/21/06
-
New Data Provide In-Depth, Safety Information on Long-Term use of Evista(R)
- Doctor's Guide, 9/28/05
-
Raloxifene May Help Prevent Endometrial Cancer - Doctor's Guide, 5/18/05
-
Evista May Help Prevent Endometrial Cancer - WebMD, 5/16/05
-
Long-Term Data Show Raloxifene May Protect Against Invasive Breast Cancer
- Doctor's Guide, 5/11/05
-
Osteoporosis Drug May Help Preserve Memory - WebMD, 4/8/05
-
Less Cognitive Impairment Seen in Women Taking Drug for Osteoporosis -
Doctor's Guide, 4/7/05 - "The drug, raloxifene,
modulates the activity of the hormone estrogen ... the 120 mg dose conferred
a 33% lower risk of developing mild cognitive impairment when compared with
the 60 mg dose and with placebo. The 60 mg dose offered no apparent
prevention of cognitive impairment. While researchers also observed a
reduced risk of developing Alzheimer's disease, that reduction was of
borderline statistical significance"
-
Study Finds Continued Reduction In Breast Cancer Incidence Associated With
Longer Use Of Raloxifene - Science Daily, 12/14/04
-
Osteo Drug May Prevent Breast Cancer - HealthDay, 11/30/04 -
"That trial lasted four years and found that the
incidence of breast cancer was 72 percent lower in women taking raloxifene
than it was in women taking a placebo"
-
Raloxifene Protective against Breast Cancer Regardless of HRT Use -
Doctor's Guide, 11/4/04
-
Osteoporosis Drug May Prevent Breast Cancer - WebMD, 11/2/04
-
Raloxifene Appears to be Associated With Doubled Risk OF Venous
Thromboembolic Event Over Long Term - Doctor's Guide, 10/11/04
-
Long-Term Raloxifene Associated With Halving of Breast-Cancer Risk in
Post-menopausal Women - Doctor's Guide, 6/8/04
- Osteoporosis
Drug May Prevent Breast Cancer - WebMD, 6/7/04
-
Weekly Fosamax (Alendronate) Shows Benefits Over Daily Evista (Raloxifene)
for Bone density and Bone Turnover Markers at 6 Months - Doctor's Guide,
5/21/04
-
Study Favors Premarin for Osteoporosis - HealthDay, 4/26/04 -
"three-year study ... Bone density declined by 2
percent in the placebo group, remained stable in the two raloxifene groups,
and increased by 4.6 percent in the CEE
group"
-
Alendronate May Offer Better Improvements in Bone Mineral Density and Bone
Turnover Than Raloxifene - Doctor's Guide, 4/13/04
-
Raloxifene Confers Multiple Lipid Benefits in Postmenopausal Osteoporotic
Women - Doctor's Guide, 3/8/04
-
Raloxifene For Osteoporosis Significantly Decreases Biochemical Markers Of
Bone Turnover Related To Fracture Risk - Doctor's Guide, 2/26/04
-
Long-term Raloxifene Treatment May Reduce Insulin Sensitivity - Doctor's
Guide, 2/16/04
-
'Designer' Estrogen Shows Promise for Menopausal Problems - HealthDay,
2/2/04
- Evista Stops
Growth of Uterine Fibroids - WebMD, 1/14/04
-
Alendronate Superior to Raloxifene in Increasing Bone Mineral Density -
Doctor's Guide, 10/7/03
-
Significant Increases in Bone Mineral Density With Alendronate Over
Raloxifene in Head-To-Head Study - Doctor's Guide, 10/6/03 -
"In the first head-to-study comparing a weekly
dosage of alendronate with a daily
dosage of raloxifene for postmenopausal women with osteoporosis, alendronate
produced significantly greater increases in bone mineral density (BMD) in
the spine and hip"
-
Hot Flushes Associated With Raloxifene Not as Much a Problem as Clinical
Data Suggest - Doctor's Guide, 10/3/03
-
Consistent Effect of Raloxifene on Reduction of Vertebral Fracture Risk in
Postmenopausal Women - Doctor's Guide, 9/25/03
-
Researchers Study Effects of Raloxifene on Markers of Cardiovascular Risk in
Non-Caucasian Postmenopausal Women with Osteoporosis - Doctor's Guide,
9/25/03
- Raloxifene Safe,
Effective in Postmenopausal Women - Medscape, 7/23/03
-
Raloxifene Increases Bone Mineral Density and Decreases Osteoporosis
Incidence Over 5 Years - Doctor's Guide, 7/21/03 -
"Compared with placebo, raloxifene treatment
significantly reduced values of bone turnover markers, including
osteocalcin, bone-specific alkaline phosphatase, and urinary C-telopeptide.
In addition, raloxifene treatment was associated with 2.8% increase in BMD
in the lumbar spine (P<0.001) and a 2.6% increase in total hip BMD ...
Incidence of hot flashes was higher among women taking raloxifene"
- Evista
Strengthens Bones, Safe on Uterus - WebMD, 7/18/03
- Osteoporosis
Drug [Evista] a Better HRT? - WebMD, 6/5/03
- Once-Weekly
Alendronate Superior to Raloxifene for Spine and Hip BMD - Medscape,
4/28/03
-
Raloxifene May Be Useful In Postmenopausal Primary Hyperparathyroidism -
Doctor's Guide, 3/28/03
- What’s Best for Bones?
- Dr. Weil, 3/4/03
-
Raloxifene Improves Postmenopausal Endothelial Function - Doctor's
Guide, 3/4/03
-
Endothelium-Dependent/Independent Vasodilatation Not Influenced By
Raloxifene - Doctor's Guide, 2/26/03
-
Postmenopausal Vaginal Atrophy Creams Work With Raloxifene - Doctor's
Guide, 2/19/03
-
Evista: Major Cardiovascular Benefits? - Physician's Weekly, 2/3/03 -
"Evista, a drug widely used to treat osteoporosis,
was associated with a 62% reduction in the risk of all strokes in
postmenopausal women at high risk for heart disease"
-
Raloxifene/Sodium Fluoride Produces Significant Bone Mineral Density
Increase In Postmenopausal Osteoporosis - Doctor's Guide, 1/24/03
-
Raloxifene Decreases Fracture Severity in Postmenopausal Women with
Osteoporosis - Doctor's Guide, 12/31/02
- Raloxifene Halves
Cerebrovascular Risk in Postmenopausal Women - Medscape, 11/20/02 -
"raloxifene (Evista) reduces the risk of
stroke or transient ischemic attack (TIA) in postmenopausal women by 48%
over four years"
-
Long-Term Raloxifene Effects Evaluated In Postmenopausal Women -
Doctor's Guide, 10/23/02
-
Raloxifene Continues to Prevent Vertebral Fractures at Four Years -
Doctor's Guide, 10/7/02
-
Women Less Likely to Discontinue Raloxifene than Estrogen-Progestin Therapy
- Doctor's Guide, 10/7/02
-
Direct Switch from Low-dose Estrogen to Raloxifene Supported - Doctor's
Guide, 10/7/02
- Raloxifene Safely
Reduces Vertebral Fractures After Menopause - Medscape, 10/7/02
-
Treating & Preventing Osteoporosis - Life Extension Magazine, 9/02 -
"From systematic research the best external evidence
is available for a supplementation with
calcium and vitamin D and a therapy
with the bisphosphonates alendronate
or risedronate, as well as the
selective estrogen receptor modulator raloxifene (Evista)."
- Osteoporosis
Drug May Protect Brain - WebMD, 7/24/02 -
"when elderly women were given Evista at twice the
approved osteoporosis dose, their
risk for developing a pre-Alzheimer's
condition was cut by 33% compared with women taking a placebo"
-
High-Dose Raloxifene Associated with Reduced Risk for Cognitive Impairment
- Doctor's Guide, 7/22/02
- Task Force Considers
Tamoxifen, Raloxifene to Prevent Breast Cancer - Medscape, 7/2/02
- Drugs
[tamoxifen and Evista] Prevent Breast Cancer -- for Some - WebMD, 7/1/02
-
One-Year Raloxifene Reduces Vertebral Fracture Risk In Osteoporotic Women
- Doctor's Guide, 5/28/02
-
Raloxifene Has No Effect Over Time On Postmenopausal Cardiac Function -
Doctor's Guide, 5/7/02
-
Study: Drug May Lower Heart Risks - Intelihealth, 2/20/02
- Designer Estrogen
Compares to Real Thing - WebMD, 2/19/02
-
Raloxifene, Estrogen Act Similarly On Postmenopausal Bone Tissue -
Doctor's Guide, 2/19/02
-
Insulin Sensitivity, Glycemic Control Unaffected By Raloxifene In
Postmenopausal Diabetics - Doctor's Guide, 1/29/02
- Tamoxifen, Raloxifene Show
Preclinical Cross-resistance - Doctor's Guide, 12/12/01
- Raloxifene May Add
Antidepressant Efficacy to Selective Serotonin Reuptake Inhibitor Therapy
for Depression - Doctor's Guide, 11/20/01
- Tamoxifen, Raloxifene
Prove Effective In Pre-Pubertal Gynecomastia - Doctor's Guide, 7/12/01
- Raloxifene May Be
Contraindicated in Some Ovarian Cancers - Doctor's Guide, 7/3/01
- Raloxifene Use Safe In
Postmenopausal Women With Type 2 Diabetes - Doctor's Guide, 6/25/01
-
Study Rates Estrogen Alternative [Evista/raloxifene] - Intelihealth,
4/19/01 -
"mimics estrogen in strengthening bones but without
the increased risk of breast cancer ... did not have an overall effect on
cognitive function ... Results of estrogen studies have been mixed, but
taken together they suggest the hormone reduces the risk of Alzheimer's
disease by about 30 percent"
-
No Cardiovascular Harm With Osteoporosis Drug, Raloxifene - Doctor's
Guide, 3/21/01
- Risk Of Symptomatic Spinal
Fractures Reduced With Evista (Raloxifene HCl) - Doctor's Guide,
10/31/00
- FDA Approves Evista For
Postmenopausal Osteoporosis - Doctor's Guide, 10/1/99
- Raloxifene Effective In
Postmenopausal Women With Osteoporosis - Doctor's Guide, 8/17/99
- Drug That Treats
Osteoporosis Also Decreases Risk Of Breast Cancer - Doctor's Guide,
6/15/99
- FDA Grants Priority Review
To Evista For Osteoporosis - Doctor's Guide, 6/4/99
- Evista Reduces Breast
Cancer Incidence In Postmenopausal Women - Doctor's Guide, 12/11/98
- FDA Approves CombiPatch
Hormone Replacement Therapy - Doctor's Guide, 8/10/98
- FDA Approves Estratab For
Osteoporosis Prevention - Doctor's Guide, 3/11/98
- Raloxifene Shows Promise As
Ideal Hormone Therapy For Some Women - Doctor's Guide, 1/28/98
- Evista Prevents
Osteoporosis In Postmenopausal Women - Doctor's Guide, 12/10/97
Abstracts:
Related Searches:
70629
|
|
